ScienceDirect.com - Gynecologic Oncology - Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum
Objective
To determine whether hormonal therapies
have efficacy in patients with recurrent low-grade serous carcinoma of
the ovary or peritoneum.
Methods
We searched
departmental databases for patients with histologically-confirmed,
evaluable, recurrent low-grade serous ovarian or peritoneal carcinoma
who received hormonal therapy at our institution between 1989 and 2009.
We retrospectively reviewed patients' medical records for demographic,
disease, hormonal therapy, and estrogen receptor and progesterone
receptor expression data. We used the Response Evaluation Criteria in
Solid Tumors version 1.1 to determine patients' responses to hormonal
therapy. Because patients could have received more than one evaluable
hormonal therapy regimen, we chose to define the outcome metric as
“patient-regimens.” Median time to disease progression (TTP) and overall
survival (OS) were also calculated. Regression analysis was also
performed.
Results
We identified 64 patients
with recurrent low-grade serous carcinoma of the ovary or peritoneum.
Patients' median TTP and median OS were 7.4 and 78.2 months,
respectively. Patients received 89 separate hormonal patient-regimens,
which produced an overall response rate of 9% (6 complete responses and 2
partial responses). Sixty-one percent of the patient-regimens resulted
in a progression-free survival duration of at least 6 months.
Patient-regimens involving ER +/PR + disease produced a longer median
TTP (8.9 months) than patient-regimens involving ER +/PR − disease did
(6.2 months;
p = 0.053). This difference approached but did not reach statistical significance.
Conclusions
Hormonal
therapies have moderate anti-tumor activity in patients with recurrent
low-grade serous carcinoma of the ovary or peritoneum. Further study to
determine whether ER/PR expression status is a predictive biomarker for
this rare cancer subtype is warranted.
